Administering Rituxan in R-CHOP

Last Modified: August 13, 2006


Dear OncoLink "Ask The Experts,"
I've recently started a job administering chemotherapy [to cancer patients]. Does it matter in what order R-CHOP (R= Rituxan, CHOP = chemotherapy regimen of Cyclophosphamide, Adriamycin, Vincristine, and Prednisone) is given? I was told to always give Rituxan last, even if the MD writes for it first, due to the higher incidence of side effects. Thanks for your input.


Michael Vozniak, PharmD, BCOP, Hematology/Oncology Clinical Pharmacy Specialist, responds:

There are no specific rules that I know of with regards to delivering R-CHOP. I think you could argue either way, i.e. to deliver Rituxan first or last. Depending on whether the patients are treated on an inpatient or outpatient basis, on which of the various regimens Rituxan is used in, and on the availability of lab results, Rituxan is administered both before and after chemotherapy in our institution.

The side effects can occur regardless of the sequence. If the Rituxan is given first, and there is an infusion reaction, we would typically bring the patient back the following day to receive the chemotherapy part of the regimen. If the Rituxan is given last and a reaction occurs, a delay in the chemotherapy until the next day is avoided, which is inevitably more convenient for the patient.


How to Find the Cancer Resources You Need - Brown Bag Web Chat
by OncoLink Editorial Team
June 15, 2011

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

R-CHOP Benefits Older Mantle-Cell Lymphoma Patients

Aug 9, 2012

Improved survival for older patients with R-CHOP induction, rituximab maintenance treatment

Progression-Free Survival Not Tied to R-CHOP Dose Density

Sep 21, 2011

No significant difference for patients with indolent B-cell lymphoma treated with R-CHOP-14 or -21

Standard-dose rituximab with low-dose CHOP chemotherapy effective for large B-cell lymphoma

Apr 11, 2011

Standard-dose rituximab with low-dose CHOP chemotherapy effective for large B-cell lymphoma